Stifel Financial Corp Has $547,000 Holdings in Inari Medical, Inc. (NASDAQ:NARI)

Stifel Financial Corp decreased its position in shares of Inari Medical, Inc. (NASDAQ:NARI) by 2.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 13,259 shares of the company’s stock after selling 339 shares during the quarter. Stifel Financial Corp’s holdings in Inari Medical were worth $547,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. GAMMA Investing LLC raised its position in Inari Medical by 67.2% in the third quarter. GAMMA Investing LLC now owns 1,177 shares of the company’s stock valued at $49,000 after purchasing an additional 473 shares during the last quarter. KBC Group NV increased its stake in shares of Inari Medical by 39.0% in the third quarter. KBC Group NV now owns 1,774 shares of the company’s stock valued at $73,000 after buying an additional 498 shares during the period. Benjamin F. Edwards & Company Inc. raised its holdings in Inari Medical by 39.4% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,847 shares of the company’s stock valued at $89,000 after buying an additional 522 shares during the last quarter. Covestor Ltd boosted its position in Inari Medical by 63.5% during the 3rd quarter. Covestor Ltd now owns 2,384 shares of the company’s stock worth $99,000 after buying an additional 926 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in Inari Medical during the 2nd quarter worth approximately $104,000. Institutional investors and hedge funds own 90.98% of the company’s stock.

Inari Medical Price Performance

Shares of Inari Medical stock opened at $54.03 on Friday. The stock’s 50-day moving average is $50.70 and its 200 day moving average is $48.24. Inari Medical, Inc. has a one year low of $36.73 and a one year high of $66.61. The firm has a market cap of $3.16 billion, a price-to-earnings ratio of -40.02 and a beta of 0.97.

Insider Buying and Selling at Inari Medical

In other Inari Medical news, Director William Hoffman sold 40,000 shares of Inari Medical stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $45.02, for a total value of $1,800,800.00. Following the completion of the sale, the director now directly owns 601,233 shares of the company’s stock, valued at approximately $27,067,509.66. The trade was a 6.24 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Andrew Hykes sold 3,000 shares of the stock in a transaction dated Tuesday, October 29th. The stock was sold at an average price of $50.00, for a total transaction of $150,000.00. Following the transaction, the chief executive officer now directly owns 445,310 shares in the company, valued at $22,265,500. This trade represents a 0.67 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 206,000 shares of company stock valued at $10,527,870. 10.60% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of Inari Medical in a research note on Tuesday, October 29th. Leerink Partners started coverage on Inari Medical in a report on Tuesday, September 3rd. They issued a “market perform” rating and a $47.00 price objective for the company. Truist Financial lifted their target price on Inari Medical from $50.00 to $63.00 and gave the stock a “hold” rating in a report on Wednesday, December 18th. Canaccord Genuity Group increased their price target on Inari Medical from $71.00 to $74.00 and gave the company a “buy” rating in a research note on Tuesday, October 29th. Finally, Piper Sandler lifted their price objective on Inari Medical from $50.00 to $52.00 and gave the stock a “neutral” rating in a research note on Tuesday, October 29th. Six equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $61.80.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.